Results 111 to 120 of about 13,555 (204)
BMC Cancer, 2018 Background Targeted therapy has always been the focus in developing therapeutic approaches in cancer, especially in the treatment of acute myeloid leukemia (AML).
Yafeng Zhou +4 more
doaj +1 more source
, 2016 The primary aim of this study was to evaluate the antitumor efficacy of the bromodomain inhibitor JQ1 in pancreatic ductal adenocarcinoma (PDAC) patient-derived xenograft (tumorgraft) models.
Council, L. N. +4 more
core +1 more source
EBioMedicine, 2019 Background: DNA repair deficiency accumulates DNA damage and sensitizes tumor cells to PARP inhibitors (PARPi). Based on our observation that the BET inhibitor JQ1 increases levels of DNA damage, we evaluated the efficacy of JQ1 + the PARPi olaparib in ...
Aubrey L. Miller +8 more
doaj +1 more source
JQ1 reduces oxidative stress-enhanced IL-6 and CXCL8 expression in NHBE cells.
, 2014 NHBE cells pre-treated with JQ1 but not JQ1(-) (both at 5×10−9−10−6 M) reduced IL-1β induced release of IL-6 (A) and CXCL8 (B) in a concentration-dependent manner.
Younis M. Khan (554747) +3 more
core +1 more source
BET Inhibitor JQ1 Attenuates Atrial Fibrillation Through Modulation of Fibrosis, Calcium Homeostasis, and Mitochondrial Function in a Murine Model [PDF]
Bromodomain and extraterminal domain (BET) proteins act as epigenetic regulators of gene transcription. BET inhibitors have shown therapeutic potential in various models of heart failure; however, their efficacy in atrial fibrillation (AF) remains ...
Murakoshi, Nobuyuki +7 more
core +1 more source
Polydopamine-Based Nanoparticles for Synergistic Chemotherapy of Prostate Cancer
International Journal of NanomedicineKebang Hu,1 Dongqi Zhang,1 Weiran Ma,2 Yanzhi Gu,2 Jiang Zhao,3 Xupeng Mu4 1Department of Urology, Lequn Branch, The First Hospital of Jilin University, Changchun, 130031, People’s Republic of China; 2College of Pharmacy, Jilin University, Changchun ...
Hu K, Zhang D, Ma W, Gu Y, Zhao J, Mu X
doaj
, 2022 Die niedermolekulare Verbindung (engl. small molecule) JQ1 hemmt kompetitiv die Bromodomänen der zur bromodomain and extra-terminal domain (BET) Familie gehörenden Proteine BRD2, BRD3 und BRD4, welche als epigenetische Lesedomänen auf die Transkription ...
Schlichting, Jara Pascale
core
Effects of JQ1 on P-TEFb occupancy.
, 2014 BAL17 and Raji cells were either untreated or treated with 1 µM of JQ1 for 2 hours. Recruitment of P-TEFb was detected by ChIP assays. Each experiment was analyzed in triplicate via real-time PCR, performed twice, and is reported as the mean and standard
David H. Price (31011) +8 more
core +1 more source
BET bromodomain inhibitor (JQ1) and tumor angiogenesis
Oncoscience, 2016 Bid, Hemant Kumar, Kerk, Samuel
openaire +2 more sources
Inhibidores BET. El singular compuesto (+)-JQ1 [PDF]
, 2015 The serendipitous discovery of (bromodomain extra-terminal) (BET) inhibitors, especially of the BRD4 bromodomain inhibitors, has allowed modulation of gene transcription with epigenetic drugs.
Avendaño, Carmen
core +7 more sources